CORDIS
EU research results

CORDIS

English EN

European Training Network on Antiviral Drug Development

Project information

Grant agreement ID: 642434

Status

Closed project

  • Start date

    1 March 2015

  • End date

    30 September 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 837 214,41

  • EU contribution

    € 3 837 214,41

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands

Objective

Viral infections are a major cause of disease, mortality and economic losses worldwide. Antiviral therapy is an essential instrument to control virus infections. At present, however, licensed antiviral drugs have been developed only against a limited number of viruses (e.g. HIV, HCV, influenza, herpesviruses). There is a clear and unmet need for antiviral drugs to treat infections with other important human pathogens.

Europe needs well-trained experts with multidisciplinary skills to advance the antiviral drug development field. However, few, if any, European universities or research institutes have the ability to deliver an intersectoral training programme that covers the broad spectrum of disciplines important for antiviral drug development.

The ANTIVIRALS partnership has been established to fill this gap. It consists of six outstanding European academic partners and four industrial partners (two large R&D companies, of which one is specialized in antiviral drug discovery and development, and two SMEs), and two partner organisations (incl. one SME specialised in education). All partners are leaders in their field, ensuring state-of-the-art training possibilities, and their skills are highly complementary.

ANTIVIRALS aims to introduce 15 ESRs to state-of-the-art knowledge and technology applied in antiviral drug development through both local and network-wide training activities. Individual research projects, research training workshops and intersectoral secondments will be supplemented with complementary skills courses and dissemination activities to improve career development and perspectives. The industrial partners are actively involved in the entire programme and will organize an industry-oriented conference aimed at further bridging the gap between academia and industry.

Thus, ANTIVIRALS offers talented researchers a multidisciplinary and intersectoral training programme and prepares them for a future leading role in antiviral drug development in Europe.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
3584 Cs Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 510 748,56

Participants (11)

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 510 748,56

UNIVERSITATSKLINIKUM HEIDELBERG

Germany

EU Contribution

€ 498 432,96

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 546 575,76

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 525 751,20

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 402 055,54

ARATANA THERAPEUTICS NV

Belgium

AICURIS GMBH & CO. KG

Germany

EU Contribution

€ 249 216,48

COMPLIX NV

Belgium

UNIVERSITAT WIEN

Austria

EU Contribution

€ 244 061,58

VIROVET

Belgium

EU Contribution

€ 250 560

COMPLIX LUXEMBOURG SA

Luxembourg

EU Contribution

€ 99 063,77

Partners (1)

Virology Education

Netherlands

Project information

Grant agreement ID: 642434

Status

Closed project

  • Start date

    1 March 2015

  • End date

    30 September 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 837 214,41

  • EU contribution

    € 3 837 214,41

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands